How Medical Discoveries Reach Patients
Between a result in a laboratory and a treatment in a clinic lie a decade, a billion dollars and a failure rate above ninety percent. Understanding the path explains why so many breakthroughs never arrive.
The Daily Edition2 min read
Illustrative. This article is demonstration content written to show The Daily Edition. It does not report actual events. Historical and scientific facts are attributed to real sources in the Deep Dive.
Quick Read · about 28 seconds
- What happened
- A new drug typically passes through laboratory studies, animal testing, three phases of human trials and regulatory review before approval. The process takes about ten to fifteen years, and roughly nine in ten drugs that enter human trials fail.
- Why it matters
- Headlines about breakthroughs usually describe the start of this process. Knowing where a result sits on the path is the single most useful tool for judging whether it will matter to patients, and when.
- What remains uncertain
- Whether accelerated approval pathways deliver real benefit or lower the evidence bar, and whether new trial designs and AI-assisted drug discovery will shorten timelines or merely increase the number of candidates that fail.
Most medical discoveries reported in the news will never reach a patient. That is not a scandal. It is the expected outcome of a process designed to find out which promising ideas are actually true, and most are not.
The stages
A candidate treatment begins in the laboratory, where researchers identify a target and compounds that act on it. Those that work in cells move to animals. Those that are safe and effective in animals may enter human trials, which proceed in phases: a small trial for safety, a larger one for signs of effect and dose, and a large one, often with thousands of patients, to establish benefit against the current standard. Regulators then review the evidence. Approval is followed by monitoring for rare effects that trials were too small to detect.
Where things fail
Roughly nine in ten drugs that enter human trials do not reach approval. Most fail for lack of effect, meaning that a treatment which worked in animals does not work in people. Others fail for safety. The highest failure rates are in neurology and psychiatry, where animal models predict human response poorly. The failure rate explains much of the cost: successful drugs must pay for the failures.
Shortcuts, and their price
Regulators have created faster pathways for serious conditions with few treatments, allowing approval based on early markers rather than final outcomes, with the requirement that benefit be confirmed later. These pathways have delivered genuine advances, particularly in cancer and HIV. They have also produced approvals that later confirmatory trials did not support, and the question of how to balance speed against certainty is unresolved.
Ask the Newspaper
Put a question to the research desk. Answers draw only on this article’s verified material and its continuing story, and every statement is cited. No language model is configured, so answers are the most relevant verified passages rather than generated prose.
Claims and evidence
Each claim is classified and linked to the evidence behind it. Illustrative evidence attributes demonstration scenarios and is marked.
Roughly nine in ten drugs entering human clinical trials do not reach approval.
Fact · confidence medium
- Clinical Development Success Rates 2011–2020 · BIO / Informa / QLSIndustry analysis; estimates vary by therapeutic area and method.
Audio version: not yet available. Listening will use the same verified text as this article. The control will appear here once narration is produced.
Related reading
The Promise and Limitations of Personalized Medicine
Sequencing a genome costs less than a night in a hospital. Turning that information into better treatment has proved far harder than the price curve suggested.
2 min read